Robert Waltermire
Fortuna: 3 M $ al 31/07/2026
Fortuna: 3 M $ al 31/07/2026
Robert Waltermire is currently the Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals, Inc. He previously worked at Venatorx Pharmaceuticals, Inc. as the Senior Vice President-CMC from 1988 to 2020.
Waltermire completed his undergraduate degree at Franklin & Marshall College in 1984 and obtained his doctorate from the University of Maryland in 1988.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 05/03/2025 | 5.789 ( 0,03 % ) | 3 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/08/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | Corporate Officer/Principal | 01/01/2020 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | Health Technology |
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.